• Anne M. Fourie
Part of the Proteases in Biology and Disease book series (PBAD, volume 4)


The ADAM family of disintegrin metalloproteases plays important roles in proteolytic “ectodomain shedding” and adhesion functions. Currently, this family has 34 members, approximately half of which are predicted to be active proteases, including ADAM28. ADAM28 is expressed in human lymphocytes, murine thymic epithelial cells, the epididymis in multiple species, and is upregulated in certain cancer cells. Both membrane-bound and secreted isoforms of ADAM28 have been identified. ADAM28 is activated by autocatalytic removal of the pro-domain and the mature transmembrane protein is expressed on the cell surface. The active form of ADAM28 cleaves specific sites in numerous peptides and protein substrates, including the low affinity IgE receptor, CD23, and IGFBP-3. The substrate selectivity of ADAM28 is very similar to that of the closely-related ADAMs, −8 and −15, but distinct from that of the more distantly-related ADAM17. An extended region of the disintegrin domain of ADAM28 specifically recognizes the leukocyte integrin, α4β1, in an activation-dependent conformation. The physiological functions of ADAM28 are not known, but its expression pattern, together with its substrate and integrin binding selectivity, suggest potential roles in spermatogenesis, lymphocyte maturation and function, inflammation and cancer.

Key words

metalloprotease lymphocyte thymic epithelium epididymis MDC-L eMDC II autocatalytic CD23 IGFBP-3 disintegrin α4β1 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bates, E.E., W.H. Fridman, and C.G. Mueller. 2002. The ADAMDEC1 (decysin) gene structure: evolution by duplication in a metalloprotease gene cluster on chromosome 8p12. Immunogenetics. 54:96–105.PubMedCrossRefGoogle Scholar
  2. Becherer, J.D., and C.P. Blobel. 2003. Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol. 54:101–23.PubMedGoogle Scholar
  3. Bode, W., F.X. Gomis-Ruth, and W. Stockler. 1993. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the ‘metzincins’. FEBS Lett. 331:134–40.PubMedCrossRefGoogle Scholar
  4. Bonnefoy, J.Y., C. Plater-Zyberk, S. Lecoanet-Henchoz, J.F. Gauchat, J.P. Aubry, and P. Graber. 1996. A new role for CD23 in inflammation. Immunol Today. 17:418–20.PubMedCrossRefGoogle Scholar
  5. Bridges, L.C., K.R. Hanson, P.H. Tani, T. Mather, and R.D. Bowditch. 2003. Integrin alpha4beta1-dependent adhesion to ADAM 28 (MDC-L) requires an extended surface of the disintegrin domain. Biochemistry. 42:3734–41.PubMedCrossRefGoogle Scholar
  6. Bridges, L.C., P.H. Tani, K.R. Hanson, C.M. Roberts, M.B. Judkins, and R.D. Bowditch. 2002. The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1. J Biol Chem. 277:3784–92.PubMedCrossRefGoogle Scholar
  7. Cerretti, D.P., R.F. DuBose, R.A. Black, and N. Nelson. 1999. Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. Biochem Biophys Res Commun. 263:810–5.PubMedCrossRefGoogle Scholar
  8. Chigaev, A., G.J. Zwartz, T. Buranda, B.S. Edwards, E.R. Prossnitz, and L.A. Sklar. 2004. Conformational Regulation of {alpha}4{beta}1-Integrin Affinity by Reducing Agents: “Inside-Out” Signaling Is Independent Of And Additive To Reduction-Regulated Integrin Activation. J. Biol. Chem. 279:32435–32443.PubMedCrossRefGoogle Scholar
  9. Cornwall, G.A., and N. Hsia. 1997. ADAM7, a member of the ADAM (a disintegrin and metalloprotease) gene family is specifically expressed in the mouse anterior pituitary and epididymis. Endocrinology. 138:4262–72.PubMedCrossRefGoogle Scholar
  10. Dalloul, A.H., C. Fourcade, P. Debre, and M.D. Mossalayi. 1991. Thymic epithelial cell-derived supernatants sustain the maturation of human prothymocytes: involvement of interleukin 1 and CD23. Eur J Immunol. 21:2633–6.PubMedGoogle Scholar
  11. Delespesse, G., M. Sarfati, C.Y. Wu, S. Fournier, and M. Letellier. 1992. The low-affinity receptor for IgE. Immunol Rev. 125:77–97.PubMedCrossRefGoogle Scholar
  12. Duffy, M.J., D.J. Lynn, A.T. Lloyd, and C.M. O’Shea. 2003. The ADAMs family of proteins: from basic studies to potential clinical applications. Thromb Haemost. 89:622–31.PubMedGoogle Scholar
  13. Fourie, A.M., F. Coles, V. Moreno, and L. Karlsson. 2003. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem. 278:30469–77.PubMedCrossRefGoogle Scholar
  14. Gagro, A., and S. Rabatic. 1994. Allergen-induced CD23 on CD4+ T lymphocytes and CD21 on B lymphocytes in patients with allergic asthma: evidence and regulation. Eur J Immunol. 24:1109–14.PubMedGoogle Scholar
  15. Gilcrease, M.Z., L. Truong, and R.W. Brown. 1996. Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum Pathol. 27:1355–60.PubMedCrossRefGoogle Scholar
  16. Glassey, B., and A. Civetta. 2004. Positive selection at reproductive ADAM genes with potential intercellular binding activity. Mol Biol Evol. 21:851–9.PubMedCrossRefGoogle Scholar
  17. Haidl, I.D., G. Huber, and K. Eichmann. 2002. An ADAM family member with expression in thymic epithelial cells and related tissues. Gene. 283:163–70.PubMedCrossRefGoogle Scholar
  18. Howard, L., R.A. Maciewicz, and C.P. Blobel. 2000. Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. Biochem J. 348 Pt 1:21–7.PubMedCrossRefGoogle Scholar
  19. Howard, L., Y. Zheng, M. Horrocks, R.A. Maciewicz, and C. Blobel. 2001. Catalytic activity of ADAM28. FEBS Lett. 498:82–6.PubMedCrossRefGoogle Scholar
  20. Jin, J., Z. Gao, L. Guo, J. Yang, and Y. Yu. 2003. Altered expression of zinc finger proteins, ADAMs, and integrin-related proteins following treatment of cultured human cells with a low concentration of N-methyl-N′-nitro-N-nitrosoguanidine. Environ Mol Mutagen. 41:344–52.PubMedCrossRefGoogle Scholar
  21. Jury, J.A., A.C. Perry, and L. Hall. 1999. Identification, sequence analysis and expression of transcripts encoding a putative metalloproteinase, eMDC II, in human and macaque epididymis. Mol Hum Reprod. 5:1127–34.PubMedCrossRefGoogle Scholar
  22. Kashiwagi, M., M. Tortorella, H. Nagase, and K. Brew. 2001. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem. 276:12501–4.PubMedCrossRefGoogle Scholar
  23. Krätzschmar, J., L. Lum, and C.P. Blobel. 1996. Metargidin, a Membrane-anchored Metalloprotease-Disintegrin Protein with an RGD Integrin Binding Sequence. J. Biol. Chem. 271:4593–4596.PubMedCrossRefGoogle Scholar
  24. Mochizuki, S., M. Shimoda, T. Shiomi, Y. Fujii, and Y. Okada. 2004. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem Biophys Res Commun. 315:79–84.PubMedCrossRefGoogle Scholar
  25. Moss, M.L., and J.W. Bartsch. 2004. Therapeutic benefits from targeting of ADAM family members. Biochemistry. 43:7227–35.PubMedCrossRefGoogle Scholar
  26. Neeson, P.J., P.J. Thurlow, G.P. Jamieson, and C. Bradley. 2003. Lymphocyte-facilitated tumour cell adhesion to endothelial cells: the role of high affinity leucocyte integrins. Pathology. 35:50–5.PubMedCrossRefGoogle Scholar
  27. Oh, J., and C. Cho. 2003. Rattus norvegicus ADAM28 isoform-1 mRNA. unpublished. NM_181693.Google Scholar
  28. Roberts, C.M., P.H. Tani, L.C. Bridges, Z. Laszik, and R.D. Bowditch. 1999. MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes. J Biol Chem. 274:29251–9.PubMedCrossRefGoogle Scholar
  29. Roemer, A., L. Schwettmann, M. Jung, J. Roigas, G. Kristiansen, D. Schnorr, S.A. Loening, K. Jung, and R. Lichtinghagen. 2004. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep. 11:529–36.PubMedGoogle Scholar
  30. Salomon, D.R., L. Crisa, C.F. Mojcik, J.K. Ishii, G. Klier, and E.M. Shevach. 1997. Vascular cell adhesion molecule-1 is expressed by cortical thymic epithelial cells and mediates thymocyte adhesion. Implications for the function of alpha4beta1 (VLA4) integrin in T-cell development. Blood. 89:2461–71.PubMedGoogle Scholar
  31. Seals, D.F., and S.A. Courtneidge. 2003. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:7–30.PubMedCrossRefGoogle Scholar
  32. Vella, A., P. Bellavite, A. Adami, R. Ortolani, G. Benoni, A. Carletto, D. Biasi, P. Caramaschi, and G. Tridente. 1999. Expression of FCepsilonII/CD23 on human neutrophils isolated from rheumatoid arthritis patients. Inflammation. 23:471–9.PubMedCrossRefGoogle Scholar
  33. Wheeler, D.J., S. Parveen, K. Pollock, and R.J. Williams. 1998. Inhibition of sCD23 and immunoglobulin E release from human B cells by a metalloproteinase inhibitor, GI 129471. Immunology. 95:105–10.PubMedCrossRefGoogle Scholar
  34. White, J.M. 2003. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol. 15:598–606.PubMedCrossRefGoogle Scholar
  35. Worley, J.R., M.D. Baugh, D.A. Hughes, D.R. Edwards, A. Hogan, M.J. Sampson, and J. Gavrilovic. 2003. Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem. 278:51340–6.PubMedCrossRefGoogle Scholar
  36. Xie, D., A. Jauch, C.W. Miller, C.R. Bartram, and H.P. Koeffler. 2002. Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex FISH and comparative genomic hybridization. Int J Oncol. 21:499–507.PubMedGoogle Scholar
  37. Zou, J., F. Zhu, J. Liu, W. Wang, R. Zhang, C.G. Garlisi, Y.H. Liu, S. Wang, H. Shah, Y. Wan, and S.P. Umland. 2004. Catalytic activity of human ADAM33. J Biol Chem. 279:9818–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Anne M. Fourie
    • 1
  1. 1.Johnson & Johnson Pharmaceutical Research and DevelopmentSan DiegoUSA

Personalised recommendations